[Federal Register Volume 77, Number 10 (Tuesday, January 17, 2012)]
[Notices]
[Pages 2299-2301]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-638]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2012-N-0018]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Healthcare Professional Survey of Prescription Drug
Promotion
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
[[Page 2300]]
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal Agencies are required to publish notice in the
Federal Register concerning each proposed collection of information and
to allow 60 days for public comment in response to the notice. This
notice solicits comments on the Healthcare Professional Survey of
Prescription Drug Promotion. This survey is designed to explore the
opinions and perceptions of physicians, nurse practitioners, and
physician assistants with regard to the promotion of prescription drugs
to consumers and healthcare providers.
DATES: Submit either electronic or written comments on the collection
of information by March 19, 2012.
ADDRESSES: Submit electronic comments on the collection of information
to http://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Juanmanuel Vilela, Office of
Information Management, Food and Drug Administration, 1350 Piccard Dr.
PI50-400B, Rockville, MD 20850, (301) 796-7651,
[email protected].
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information before
submitting the collection to OMB for approval. To comply with this
requirement, FDA is publishing notice of the proposed collection of
information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Healthcare Professional Survey of Prescription Drug Promotion--(OMB
Control Number 0910--New)
I. Regulatory Background
Section 1701(a)(4) of the Public Health Service Act (42 U.S.C.
300u(a)(4)) authorizes the Food and Drug Administration (FDA) to
conduct research relating to health information. Section 903(d)(2)(c)
of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C.
393(d)(2)(c)) authorizes FDA to conduct research relating to drugs and
other FDA regulated products in carrying out the provisions of the FD&C
Act.
II. Description
The rise of direct-to-consumer (DTC) drug advertising and
prescription drug promotion has affected healthcare professionals in a
number of ways. First, healthcare professionals regularly encounter
patients who have been exposed to DTC ads. Second, healthcare
professionals also see and hear such ads directly as mass media
consumers themselves. Since clarification of the adequate provision
requirement for prescription drug broadcast ads in 1997, FDA has faced
numerous questions about the influence of DTC pharmaceutical marketing
because such advertising directly engages consumers and potentially
affects interactions between patients and their physicians (Refs. 1 and
2). Those questions have grown more urgent with the growth of DTC
advertising in recent years (Refs. 3 and 4). In 2002, FDA considered
this form of promotion sufficiently important as a force in the
physician-patient interaction that they surveyed both patients and
physicians regarding their perceptions of DTC advertising (Ref. 5).
Now, nearly a decade later, there are critical reasons to return to the
field to gather more evidence on the influence of DTC advertising in
the examination room and on the relationships between healthcare
professionals and patients.
One of the most noteworthy aspects of the current healthcare
environment in 2011 is the role now played by various physician
extenders. Naylor and Kurtzman (Ref. 6) recently noted that nurses are
the single largest group of healthcare providers in the United States
and they argue that nurse practitioners will play an increasingly vital
role in primary care delivery. Similarly, physician assistants also
bolster the ability of our healthcare system to offer some types of
care at lower cost. The aforementioned 2002 FDA study did not include
nurse practitioners or physician assistants in the sample; that study
focused on general practitioners and specialists in several key areas
targeted by DTC advertising. Murray and colleagues (Ref. 7) also
conducted a large-scale survey of U.S. physicians regarding their
perceptions of DTC advertising, but they also did not include nurse
practitioners or physician assistants in their sample. Because DTC
advertising likely affects daily interactions between patients and
nurse practitioners and physician assistants--similar to the 2002 FDA
study that suggested the influence of advertising on physicians' work
lives--including these groups in the new sample will further
understanding of DTC advertising in the healthcare system.
Another limitation of the 2002 FDA study was the extent to which
the results were nationally representative. As FDA has acknowledged,
the initial set of results as reported were applicable to survey
respondents but were not weighted to reflect national statistics as to
the age, sex, and racial composition of the healthcare professional
population. Similar to many types of surveys that have struggled in
recent decades with declines in cooperation rates (Ref. 8), surveys of
healthcare professionals in general often can benefit from weighting to
reduce nonresponse bias. The current survey will include weighted
responses from respondents that will reflect national demographic
patterns.
Over the past decade, researchers have been able to better assess
how DTC advertising has unfolded in the United States and determine the
questions that warrant further survey work. For example, researchers
have worried for a number of years that DTC advertising might produce
adverse outcomes, such as clinically inappropriate patient requests for
drugs or patient overestimation of the efficacy of advertised
medications (Refs. 5, 7, 9, and 10). At the same time, the 2002 FDA
[[Page 2301]]
survey found that roughly as many physicians thought DTC advertising
had a positive effect on their practice as those who thought there had
been a negative influence. Moreover, the 2002 FDA survey found that
roughly a third of physicians surveyed thought that DTC advertising had
essentially no influence on their practice. The question of whether a
similar pattern will emerge now, despite the growth of DTC advertising,
is a vital one. Furthermore, FDA will benefit from knowing more detail
about the various types of perceived effects DTC advertising might
have. For example, some healthcare professionals might be ambivalent
rather than strongly in favor of or opposed to DTC advertising. In
addition, with the proliferation of social media platforms, the
emergence of online pharmaceutical marketing, and the evolution of
office detailing practices (Refs. 11 and 12), FDA will benefit by
knowing more about healthcare professionals' awareness of new and
emerging drug promotion sites and practices. The proposed survey will
address these issues.
III. Method Overview
We propose a nationally representative sample of healthcare
professionals that will yield 2,000 responses from 500 general
practitioners, 500 specialists, 500 nurse practitioners, and 500
physician assistants. Such a design will help to ensure our ability to
discuss not only healthcare professional perceptions generally but also
to assess potential variation between different types of healthcare
professionals. This sample will be recruited from a national Internet
healthcare professional panel that includes over 70,000 individuals
originating from the American Medical Association master file and other
medical organizations. Because there are not enough individuals in this
panel to satisfy the needs of the proposed project, nurse practitioners
and physician assistants will be specially recruited from relevant
professional organizations.
Healthcare providers are a difficult group to recruit, and so
several strategies will be put into place to achieve a high response
rate. These include sending prenotification letters before online
invitation, lengthening the data collection period to 8 weeks (from the
more typical 4 weeks), tailoring contact materials, disclosing FDA
sponsorship on survey materials, and conducting reminder telephone
calls. Appropriate weighting will be applied to adjust for any survey
nonresponse as well as any noncoverage or undersampling and
oversampling resulting from the sample design.
Participants who agree to participate will answer questions online.
The survey is expected to take no longer than 20 minutes. This will be
a one-time (versus annual) data collection.
FDA estimates the burden of this collection of information as
follows: The total respondent sample for this data collection is 2,025.
We will sample 25 respondents for basic programming pretesting and
2,000 respondents for the full study. We estimate the response burden
to be 20 minutes, for a burden of 1,008 hours.
Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Activity Number of responses per Total annual per response Total hours
respondents respondent responses (in hours)
----------------------------------------------------------------------------------------------------------------
Screener........................ 10,000 1 10,000 2/60 333
Pretest......................... 25 1 25 20/60 8
Main Study...................... 2,000 1 2,000 20/60 667
-------------------------------------------------------------------------------
Total....................... .............. .............. .............. .............. 1,008
----------------------------------------------------------------------------------------------------------------
There are no capital costs or operating and maintenance costs associated with this collection of information.
IV. References
The following references have been placed on display in the
Division of Dockets Management (see ADDRESSES) and may be seen by
interested persons between 9 a.m. and 4 p.m., Monday through Friday.
1. Fintor, L., ``Direct-to-Consumer Marketing: How Has It
Fared?,'' Journal of the National Cancer Institute, 94, 329-331,
2002.
2. Palumbo, F.B. and C.D. Mullins, ``The Development of Direct-
to-Consumer Prescription Drug Advertising Regulations,'' Food and
Drug Law Journal, 57, 423-443, 2002.
3. Curry, T.J., J. Jarosch, and S. Pacholok, ``Are Direct to
Consumer Advertisements of Prescription Drugs Educational? Comparing
1992 to 2002,'' Journal of Drug Education, 35, 2172-2232, 2005.
4. Government Accountability Office (GAO), ``Improvements Needed
in FDA's Oversight of Direct-to-Consumer Advertising, GAO-07-54,
Washington, DC: GAO, November 16, 2006.
5. Aikin, K.J., J.L. Swasy, and A.C. Braman, ``Patient and
Physician Attitudes and Behaviors Associated With DTC Promotion of
Prescription Drugs,'' Washington, DC: Food and Drug Administration,
November 19, 2004.
6. Naylor, M.D. and E.T. Kurtman, ``The Role of Nurse
Practitioners in Reinventing Primary Care,'' Health Affairs, 29,
893-899, 2010.
7. Murray, E., B. Lo, L. Pollack, et al., ``Direct-to-Consumer
Advertising: Physicians' Views of Its Effects on Quality of Care and
the Doctor-Patient Relationship,'' Journal of the American Board of
Family Practice, 16, 513-524, 2003.
8. Dey, E.L., ``Working With Low Survey Response Rates: The
Efficacy of Weighting Adjustments,'' Research in Higher Education,
38, 215-227, 1997.
9. Mintzes, B., M.L. Barer, R.L. Kravitz, et al., ``Influence of
Direct-to-Consumer Pharmaceutical Advertising and Patients' Requests
on Prescribing Decisions: Two Site Cross Sectional Study,'' British
Medical Journal, 324, 278-279, 2002.
10. Mitra, A., J. Swasy, and K. Aikin, ``How Do Consumers
Interpret Market Leadership Claims in Direct-to-Consumer Advertising
of Prescription Drugs?,'' Advances in Consumer Research, 33, 381-
387, 2006.
11. Donohue, J.M., M. Cevasco, and M.B. Rosenthal, ``A Decade of
Direct-to-Consumer Advertising of Prescription Drugs,'' New England
Journal of Medicine, 357, 673-681, 2007.
12. Chew, L.D., T.S. O'Young, T.K. Hazlet, et al., ``A Physician
Survey of the Effect of Drug Sample Availability on Physician's
Behavior,'' Journal of General Internal Medicine, 15, 478-483, 2000.
Dated: January 10, 2012.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2012-638 Filed 1-13-12; 8:45 am]
BILLING CODE 4160-01-P